Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 267

1.

A long term follow-up of a randomized trial comparing interferon-alpha with busulfan for chronic myelogenous leukemia. The Kouseisho Leukemia Study Group.

Ohnishi K, Tomonaga M, Kamada N, Onozawa K, Kuramoto A, Dohy H, Mizoguchi H, Miyawaki S, Tsubaki K, Miura Y, Omine M, Kobayashi T, Naoe T, Ohshima T, Hirashima K, Ohtake S, Takahashi I, Morishima Y, Naito K, Asou N, Tanimoto M, Sakuma A, Ohno R.

Leuk Res. 1998 Sep;22(9):779-86.

PMID:
9716008
2.

A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase.

Ohnishi K, Ohno R, Tomonaga M, Kamada N, Onozawa K, Kuramoto A, Dohy H, Mizoguchi H, Miyawaki S, Tsubaki K, et al.

Blood. 1995 Aug 1;86(3):906-16.

3.

Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group.

Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queisser W, Löffler H, Hochhaus A, Heinze B, et al.

Blood. 1994 Dec 15;84(12):4064-77.

4.

Multicenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia. Kouseisho Leukemia Study Group.

Ohnishi K, Minami S, Ueda T, Nishimura M, Tsubaki K, Takemoto Y, Takeshita A, Sao H, Kageyama S, Ueda R, Ohno R.

Int J Hematol. 2000 Aug;72(2):229-36.

PMID:
11039674
5.

Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: the main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-alpha. Results of the CML89 trial of the Spanish Collaborative Group on interferon-alpha2a and CML.

Steegmann JL, Odriozola J, Rodriguez-Salvanés F, Giraldo P, García-Laraña J, Ferro MT, Benítez E, Pérez-Pons C, Giralt M, Escribano L, Lavilla E, Miguel A, Areal C, Pérez-Encinas M, Abad A, Maldonado J, Massagué I, Fernández-Rañada JM.

Haematologica. 1999 Nov;84(11):978-87.

6.

Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.

Kantarjian HM, Talpaz M, O'Brien S, Smith TL, Giles FJ, Faderl S, Thomas DA, Garcia-Manero G, Issa JP, Andreeff M, Kornblau SM, Koller C, Beran M, Keating M, Rios MB, Shan J, Resta D, Capdeville R, Hayes K, Albitar M, Freireich EJ, Cortes JE.

Clin Cancer Res. 2002 Jul;8(7):2177-87.

7.

Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.

Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Rios MB, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Verstovsek S, Wierda W, Keating M, Talpaz M.

Cancer. 2003 Dec 15;98(12):2636-42.

8.

Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service.

Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M.

Ann Intern Med. 1995 Feb 15;122(4):254-61.

PMID:
7825760
9.

Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583.

Ozer H, George SL, Schiffer CA, Rao K, Rao PN, Wurster-Hill DH, Arthur DD, Powell B, Gottlieb A, Peterson BA, Rai K, Testa JR, LeBeau M, Tantravahi R, Bloomfield CD.

Blood. 1993 Nov 15;82(10):2975-84.

10.

Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.

Kantarjian HM, O'Brien S, Smith TL, Rios MB, Cortes J, Beran M, Koller C, Giles FJ, Andreeff M, Kornblau S, Giralt S, Keating MJ, Talpaz M.

J Clin Oncol. 1999 Jan;17(1):284-92.

PMID:
10458244
11.
12.

Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha.

Kantarjian HM, Cortes JE, O'Brien S, Luthra R, Giles F, Verstovsek S, Faderl S, Thomas D, Garcia-Manero G, Rios MB, Shan J, Jones D, Talpaz M.

Blood. 2004 Oct 1;104(7):1979-88. Epub 2004 Jun 15.

15.

Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis.

Kantarjian HM, O'Brien S, Cortes JE, Shan J, Giles FJ, Rios MB, Faderl SH, Wierda WG, Ferrajoli A, Verstovsek S, Keating MJ, Freireich EJ, Talpaz M.

Cancer. 2003 Feb 15;97(4):1033-41.

16.
17.

Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.

O'Brien S, Talpaz M, Cortes J, Shan J, Giles FJ, Faderl S, Thomas D, Garcia-Manero G, Mallard S, Beth M, Koller C, Kornblau S, Andreeff M, Murgo A, Keating M, Kantarjian HM.

Cancer. 2002 Apr 1;94(7):2024-32.

18.

Prolonged chronic phase in chronic myelogenous leukemia after homoharringtonine therapy.

Li YF, Deng ZK, Xuan HB, Zhu JB, Ding BH, Liu XN, Chen BA.

Chin Med J (Engl). 2009 Jun 20;122(12):1413-7.

PMID:
19567163
19.
20.

The German CML study, comparison of busulfan vs. hydroxyurea vs. interferon alpha and establishment of prognostic score 1.

Hehlmann R, Heimpel H, Kolb HJ, Heinze B, Hochhaus A, Griesshammer M, Pralle H, Queisser WP, Essers U, Falge C, et al.

Leuk Lymphoma. 1993;11 Suppl 1:159-68.

PMID:
8251890
Items per page

Supplemental Content

Write to the Help Desk